<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04513600</url>
  </required_header>
  <id_info>
    <org_study_id>20-02</org_study_id>
    <nct_id>NCT04513600</nct_id>
  </id_info>
  <brief_title>ATTR-Cardiomyopathy Stabilization Following Tafamidis Therapy</brief_title>
  <official_title>Transthyretin Amyloid Cardiomyopathy: Stabilization Assessed by Cardiac Magnetic Resonance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Christ Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Christ Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will investigate the stabilization effects of Tafamidis utilizing cardiac imaging&#xD;
      cardiac magnetic resonance imaging (CMR). The investigators propose to pursue the following&#xD;
      specific aims:&#xD;
&#xD;
        1. Utilize cardiac magnetic resonance to assess stabilization of ATTR after Tafamidis&#xD;
           therapy based on extracellular volume mapping.&#xD;
&#xD;
        2. Investigate left ventricular myocardial mass, native T1, T2, and extracellular volume&#xD;
           mapping after 12 month follow-up.&#xD;
&#xD;
        3. Utilize cardiac magnetic resonance feature tracking at baseline and at 12 month&#xD;
           follow-up.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators hypothesize that participants with earlier stages (NYHA Class I and Class&#xD;
      II) of ATTR wild type and ATTR mutant will demonstrate stabilization of ATTR following 1 year&#xD;
      of Tafamidis.&#xD;
&#xD;
      The investigators propose to pursue the following specific aims:&#xD;
&#xD;
        1. Utilize cardiac magnetic resonance to assess stabilization of ATTR after Tafamidis&#xD;
           therapy based on extracellular volume mapping.&#xD;
&#xD;
        2. Investigate left ventricular myocardial mass, native T1, T2, and extracellular volume&#xD;
           mapping after 12 month follow-up.&#xD;
&#xD;
        3. Utilize cardiac magnetic resonance feature tracking at baseline and at 12 month&#xD;
           follow-up.&#xD;
&#xD;
      The investigators will enroll 131 participants with confirmed ATTR. Participants will be&#xD;
      screened to exclude light chain amyloidosis by either measuring the proportion of kappa:&#xD;
      lambda light chains with the serum free light chain assay, and tested for immunofixation&#xD;
      electrophoresis of serum and urine. Once participants has confirmed diagnosis of ATTR&#xD;
      (pyrophosphate scan positive scoring &gt;1.5 ratio) and undergone baseline testing participants&#xD;
      will be ask to enroll in the study. Genetic testing will performed to further distinguish&#xD;
      between mutation and wild type. All participants will be required to sign informed consent&#xD;
      agreeing to follow up testing at 1 year.&#xD;
&#xD;
      Participants will undergo a baseline cardiac magnetic resonance imaging for the purpose of&#xD;
      evaluating native T1, T2, first pass perfusion, and extracellular volumes for patients with&#xD;
      glomerular filtration rate &gt;30. Patients with glomerular filtration rate &lt;30 will only have&#xD;
      native T1 and T2 values evaluated. If participants undergo implanted cardiac device during&#xD;
      Tafamidis therapy, follow up cardiac magnetic resonance imaging will only evaluate featuring&#xD;
      tracking and left ventricular mass. Left ventricular mass and cardiac magnetic feature&#xD;
      tracking values will be extracted from all cardiac magnetic resonance imaging studies. After&#xD;
      one year of Tafamidis therapy, participants will return to initial facility where testing was&#xD;
      preformed to undergo a follow up cardiac magnetic resonance imaging study.&#xD;
&#xD;
      There is emerging evidence that there may be biomarkers yet identified for earlier detection&#xD;
      of this disease. Henceforth, investigators propose to collect and store blood samples for all&#xD;
      participants for future analyses.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Stabilization of Transthyretin Amyloid Cardiomyopathy</measure>
    <time_frame>1 year</time_frame>
    <description>Stabilization as defined by reduction in extracellular volume on cardiac magnetic resonance after one year of Tafamidis therapy</description>
  </primary_outcome>
  <enrollment type="Anticipated">131</enrollment>
  <condition>Transthyretin Amyloidosis</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cardiac MRI</intervention_name>
    <description>Lab work: Hs- Troponin, Serum N-terminal-proBNP CMR: Native T1, Native T2, extracellular volume, strain and strain rate.</description>
    <other_name>Blood sample</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        131 patients diagnosed with ATTR-CM being treated with Tafamidis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients will be included if they meet the following criteria:&#xD;
&#xD;
               -  18 and 90 years of age&#xD;
&#xD;
               -  Transthyretin amyloid cardiomyopathy (ATTRwt or ATTRm) confirmed by genetic&#xD;
                  testing and/or presence of transthyretin precursor protein confirmed on&#xD;
                  immunohistochemical analysis, and/or scintigraphy&#xD;
&#xD;
               -  History of heart failure (NYHA I, II, or III)&#xD;
&#xD;
               -  Agreeable to treatment with Tafamidis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients will be excluded if any one of the following criteria are not met:&#xD;
&#xD;
               -  Heart failure not due to transthyretin amyloid cardiomyopathy&#xD;
&#xD;
               -  New York Heart Association (NYHA) class IV heart failure&#xD;
&#xD;
               -  Presence of light-chain amyloidosis (serum or urine)&#xD;
&#xD;
               -  Implanted cardiac device at baseline&#xD;
&#xD;
               -  Treatment with ATTR stabilizer or gene silencer within the past 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wojciech Mazur, MD</last_name>
    <phone>513-206-1120</phone>
    <email>wojciech.mazur@thechristhospital.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cassady Palmer, BS</last_name>
    <phone>513-585-1400</phone>
    <email>cassady.palmer@thechristhospital.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wojciech Mazur, MD</last_name>
      <phone>513-206-1120</phone>
      <email>wojciech.mazur@thechristhospital.com</email>
    </contact>
    <contact_backup>
      <last_name>Cassady Palmer, BS</last_name>
      <phone>513-585-1400</phone>
      <email>cassady.palmer@thechristhospital.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 12, 2020</study_first_submitted>
  <study_first_submitted_qc>August 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2020</study_first_posted>
  <last_update_submitted>January 25, 2021</last_update_submitted>
  <last_update_submitted_qc>January 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Christ Hospital</investigator_affiliation>
    <investigator_full_name>Dr. Wojciech Mazur</investigator_full_name>
    <investigator_title>Director of Advanced Cardiac Imaging</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

